The pharmacologic basis for antibody-auristatin conjugate activity

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 3, 2009, Pages 932-938

  Alley, Stephen C ^a   Zhang, Xinqun ^a   Okeley, Nicole M ^a   Anderson, Martha ^a   Law, Che Leung ^a   Senter, Peter D ^a   Benjamin, Dennis R ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY H1F6 MONOMETHYLAURISTATIN F CONJUGATE; MONOMETHYLAURISTATIN; SGN 75; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONJUGATE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TARGETING; DRUG TUMOR LEVEL; HEPATOBILIARY SYSTEM; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYSTEMIC CIRCULATION; TUMOR XENOGRAFT;

AMINOBENZOIC ACIDS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HALF-LIFE; IMMUNOTOXINS; ISOTOPE LABELING; MICE; MICE, NUDE; OLIGOPEPTIDES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349083423     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.155549     Document Type: Article

References (39)

1. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, and Senter PD (2008) Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19:759-765.
2. Boghaert ER, Khandke KM, Sridharan L, Dougher M, DiJoseph JF, Kunz A, Hamann PR, Moran J, Chaudhary I, and Damle NK (2008) Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 mul) blood samples. Cancer Chemother Pharmacol 61:1027-1035.
3. Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, Tice DA, and Chen X (2007) Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging 34:2024-2036. (Pubitemid 350212123)
4. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357.
5. Carter PJ and Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154-169.
6. Doronina SO, Mendelsohn BA, Bovee TD, Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki BE, Sanderson RJ, Zabinski RF, et al. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124. (Pubitemid 43157592)
7. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, et al. (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784. (Pubitemid 36791396)
8. Ferl GZ, Kenanova V, Wu AM, and DiStefano JJ III (2006) A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 5:1550-1558. (Pubitemid 44070492)
9. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, et al. (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063-7070. (Pubitemid 39383058)
10. Henderson LA, Baynes JW, and Thorpe SR (1982) Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys 215:1-11.
11. Ishitsuka K, Jimi S, Goldmacher VS, Ab O, and Tamura K (2008) Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol 141:129-131. (Pubitemid 351347531)
12. Kim KM, McDonagh CF, Westendorf L, Brown LL, Sussman D, Feist T, Lyon R, Alley SC, Okeley NM, Zhang X, et al. (2008) Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 7:2486-2497.
13. Kovtun YV and Goldmacher VS (2007) Cell killing by antibody-drug conjugates. Cancer Lett 255:232-240.
14. Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, et al. (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66:2328-2337. (Pubitemid 43294947)
15. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280-9290.
16. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, and Olson WC (2006) Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 12:2591-2596.
17. McDonagh CF, Kim KM, Turcott E, Brown LL, Westendorf L, Feist T, Sussman D, Stone I, Anderson M, Miyamoto J, et al. (2008) Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther 7:2913-2923.
18. McDonagh CF, Turcott E, Westendorf L, Webster JB, Alley SC, Kim K, Andreyka J, Stone I, Hamblett KJ, Francisco JA, et al. (2006) Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19:299-307. (Pubitemid 43999640)
19. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, et al. (2008) Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 14:7763-7772.
20. Moldoveanu Z, Epps JM, Thorpe SR, and Mestecky J (1988) The sites of catabolism of murine monomeric IgA. J Immunol 141:208-213. (Pubitemid 18175276)
21. Mosure KW, Henderson AJ, Klunk LJ, and Knipe JO (1997) Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Cancer Chemother Pharmacol 40:251-258.
22. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, and Gerber HP (2008a) Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 142:69-73. (Pubitemid 351783148)
23. Oflazoglu E, Stone IJ, Gordon K, Wood CG, Repasky EA, Grewal IS, Law CL, and Gerber HP (2008b) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 14:6171-6180.
24. Rodon J, Garrison M, Hammond LA, de Bono J, Smith L, Forero L, Hao D, Takimoto C, Lambert JM, Pandite L, et al. (2008) Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol 62:911-919.
25. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, and Wahl AF (2005) In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 11:843-852.
26. Sapra P, Stein R, Pickett J, Qu Z, Govindan SV, Cardillo TM, Hansen HJ, Horak ID, Griffiths GL, and Goldenberg DM (2005) Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 11:5257-5264. (Pubitemid 41003714)
27. Shargel L, Wu-Pong S, and Yu AB (2005) Applied Biopharmaceutics and Pharmacokinetics, McGraw-Hill, New York.
28. Smith-Jones PM, Pandit-Taskar N, Cao W, O'Donoghue J, Philips MD, Carrasquillo J, Konner JA, Old LJ, and Larson SM (2008) Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 35:343-351.
29. Spearman ME, Goodwin RM, Apelgren LD, and Bumol TF (1987a) Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice. J Pharmacol Exp Ther 241:695-703. (Pubitemid 17111582)
30. Spearman ME, Goodwin RM, and Kau D (1987b) Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys. Drug Metab Dispos 15:640-647. (Pubitemid 18004619)
31. Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, Handley FG, Ihle NC, Senter PD, and Alley SC (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16:1282-1290.
32. Sutherland MS, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, et al. (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 281:10540-10547. (Pubitemid 43864594)
33. Thurber GM, Schmidt MM, and Wittrup KD (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29:57-61.
34. Tse KF, Jeffers M, Pollack VA, McCabe DA, Shadish ML, Khramtsov NV, Hackett CS, Shenoy SG, Kuang B, Boldog FL, et al. (2006) CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12:1373-1382. (Pubitemid 43342531)
35. Verdier-Pinard P, Kepler JA, Pettit GR, and Hamel E (2000) Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity. Mol Pharmacol 57:180-187. (Pubitemid 30033274)
36. Vukelja S, Rugo H, Vogel C, Borson R, Tan-Chiu E, Birkner M, Agresta S, Klencke B, O'Shaughnessy J, and Burris HA (2008) A phase II study of Trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer (MBC): interim results, in 31st Annual San Antonio Breast Cancer Symposium, 2008 December 10-14. Abstract 33, San Antonio, TX.
37. Wu AM and Senter PD (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146.
38. Xie H, Audette C, Hoffee M, Lambert JM, and Blättler WA (2004) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther 308:1073-1082. (Pubitemid 38263984)
39. Younes A, Forero-Torres A, Bartlett NL, Leonard JP, Lynch C, Kennedy DA, and Sievers EL (2008) Multiple complete responses in a Phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Blood (American Society of Hematology Annual Meeting Abstracts) 112:1006.